Xenomics (XNOM) is devloping next generation molecular diagnostics products.
The company's proprietary Transrenal DNA/RNA test platform to develop highly sensitive, truly non-invasive molecular diagnostics. The patented technology uses simple urine specimens and can be applied to a broad range of products addressing multi-billion dollar markets.
They are initially targeting medical conditions in which the standard of care requires samples that are difficult, painful, or dangerous to obtain and analyze as well as conditions for which no diagnostic tests currently exist. These targets include infectious disease detection and monitoring, cancer detection and monitoring, prenatal genetic testing, monitoring organ/cell transplants, diagnosis of CNS conditions.
Xenomics has entered into non-exclusive lincensing arrangements with several pharmaceutical companies to further develop and market its products.
http://www.google.com/finance/company_news?q=PINK:XNOM
http://OxBridgeResearch.com
No comments:
Post a Comment